The effects of Rapamycin in murine peripheral nerve isografts and allografts

Plastic and Reconstructive Surgery

Volumn 109, Issue 7, 2002, Pages 2405-2417

  Myckatyn, Terence M ^a   Ellis, Ramsey A ^a   Grand, Aaron G ^a   Sen, Subhro K ^a   Lowe III, James B ^a   Hunter, Daniel A ^a   Mackinnon, Susan E ^a  

^a East Pavilion   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS;

ALLOGRAFT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; ISOGRAFT; NERVE GRAFT; NERVE INJURY; NERVE REGENERATION; NONHUMAN; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0036114008     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006534-200206000-00035     Document Type: Article

References (110)

1. The effect of duration of muscle denervation on functional recovery in the rat model
2. Clinical application of peripheral nerve transplantation
3. Nerve allotransplantation following severe tibial nerve injury
4. Immunophilins: Beyond immunosuppression
5. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin, and cyclosporin A
6. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neuroregenerative animal' models
7. Effects of FKBP-12 ligands following tibial nerve injury in rats
8. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve
9. Acceleration of peripheral nerve regeneration following FK 506 administration
10. The effect of the immunosuppressant FK506 on peripheral nerve regeneration following nerve grafting
11. FK506 accelerates functional recovery following nerve grafting in a rat model
12. FK506 rescues peripheral nerve allografts in acute rejection
13. Peripheral nerve allograft transplantation with FK506: Functional, histological, and immunological results before and after discontinuation of immunosuppression
14. Peripheral-nerve allotransplantation in rats immunosuppressed with transient or long-term FK-506
15. Clinical outcome following nerve allograft transplantation
16. The side-effects of cyclosporine-A and tacrolimus
17. Calcineurin inhibitors cause renal afferent activation in rats: A novel mechanism of cyclosporine-induced hypertension
18. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
19. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
20. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment
21. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
22. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkap-paB: Implications for tolerance induction
23. T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: Effects of cyclosporine and donor antigen
24. The first transplantation of a hand in humans: Early results
25. Human hand allograft: Report on first 6 months
26. Chemistry and biology of the immunophilins and their immunosuppressive ligands
27. Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin
28. Neural roles of immunophilins and their ligands
29. Rapamycin, but not FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell cycle progression
30. Immunosuppressive strategies in transplantation
31. Safe injection of cultured Schwann cells into peripheral nerve allografts
32. Cold preservation of nerve allografts and immunosuppression with FK506 in mice
33. An evaluation of nerve repair with nerve allografts in normal and immunologically tolerant rats
34. A practical guide to the analysis of sirolimus using high-performance liquid chromatography with ultraviolet detection
35. Analytical performance of microparticle enzyme immunoassay and HPLC-tandem mass spectrometry in the determination of sirolimus in whole blood
36. L The quantification of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and micro-particle enzyme immunoassay in renal transplant recipients
37. Determination of an improved sirolimus (rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor-specific bone marrow
38. Superiority of sirolimus (rapamycin) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow
39. The efficacy and toxicity of rapamycin in murine islet transplantation: In vitro and in vivo studies
40. Late adjunctive therapy with single doses of rapamycin in skin-allografted mice treated with antilymphocyte serum and donor bone marrow cells
41. Interand intraobserver reliability of walking-track analysis used to assess sciatic nerve function in rats
42. Functional evaluation of complete sciatic, peroneal, and posterior tibial nerve lesions in the rat
43. An index of the functional condition of rat sciatic nerve based on measurements made from walking tracks
44. Walking track analysis: Utilization of individual footprint parameters
45. Walking track analysis: A long-term assessment of peripheral nerve recovery
46. A longitudinal, functional study of peripheral nerve recovery in the mouse
47. Functional indices for sciatic, peroneal, and posterior tibial nerve lesions in the mouse
48. Peripheral nerve regeneration in CNTF knock-out mice
49. Induction of donor-specific tolerance to rat nerve allografts with portal venous donor alloantigen and anti-ICAM-1/LFA-1 monoclonal antibodies
50. Neuronal regeneration enhances the expression of the immunophilin FKBP-12
51. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase
52. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity
53. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia
54. Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats
55. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD
56. A novel immunophilin ligand: Distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease
57. Immunophilin ligands and GDNF enhance neurite branching or elongation from developing dopamine neurons in culture
58. FK506 and the role of immunophilins in nerve regeneration
59. The immunosuppressant FK506 increases GAP-43 mRNA levels in axotomized sensory neurons
60. Tacrolimus (FK506) increases neuronal expression of GAP- 43 and improves functional recovery after spinal cord injury in rats
61. Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506
62. Neuroimmunophilin ligands: Evaluation of their therapeutic potential for the treatment of neurological disorders
63. FK-506, an immunosuppressant, increases functional recovery and axonal regeneration in the rat following axotomy of the sciatic nerve
64. The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury
65. Generation and evaluation of putative neuroregenerative drugs: Part 1. Virtual point mutations to the polyketide rapamycin
66. Comparative dose-dependent study of FK506 and cyclosporin A on the rate of axonal regeneration in the rat sciatic nerve
67. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity
68. Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation
69. Control of p70 s6 kinase by kinase activity of FRAP in vivo
70. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase
71. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation
72. A signaling pathway to translational control
73. Mechanism of action of rapamycin: New insights into the regulation of G1-phase progression in eukaryotic cells
74. Discordant effects of rapamycin on proliferation and p 70S6 kinase phosphorylation in normal and neoplastic rat chromaffin cells
75. Differential effects of cyclic adenosine 3′,5′-monophosphate on p70 ribosomal S6 kinase
76. Regulation of calcineurin by growth cone calcium waves controls neurite extension
77. Comparative effects of FK-506, rapamycin and cyclosporin A, on the in vitro differentiation of dorsal root ganglia explants and septal cholinergic neurons
78. A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration
79. Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in culture and in vivo
80. Failure of GPI compounds to display neurotrophic activity in vitro and in vivo
81. Three-dimensional structure of the immunophilin-like domain of FKBP59 in solution
82. Generation and evaluation of putative neuroregenerative drugs: Part 2. Screening virtual libraries of novel polyketides which possess the binding domain of rapamycin
83. Rapamycin for immunosuppression in organ allografting
84. Sirolimus: A potent new immunosuppressant for liver transplantation
85. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey
86. Pediatric utilization of rapamycin for severe cardiac allograft rejection
87. Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients
88. Sirolimus approved with renal transplant indication
89. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
90. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs
91. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin
92. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells
93. Efficacy of rapamycin and FK 506 in prolonging rat hind limb allograft survival
94. Association of down-regulation of cytokine activity with rat hind limb allograft survival
95. Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine
96. Relative anti-genicity of components of a vascularized limb allograft
97. Long-term survival of an extremity composite tissue allograft with FK506-mycophenolate mofetil therapy
98. Limb allografts in rats immunosuppressed with FK506: I. Reversal of rejection and indefinite survival
99. Comparison of long-term immunosuppression for limb transplantation using cyclosporine, tacrolimus, and mycophenolate mofetil: Implications for clinical composite tissue transplantation
100. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154
101. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154
102. Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand
103. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
104. CD40-gp39 interactions play a critical role during allograft rejection: Suppression of allograft rejection by blockade of the CD40-gp39 pathway
105. The CD40 pathway in allograft rejection, acceptance, and tolerance
106. Transplantation tolerance: A look at the nonhuman primate literature in the light of modern tolerance theories
107. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance
108. Composite tissue allotransplantation: A comprehensive review of the literature. Part I
109. Composite tissue allotransplantation: A comprehensive review of the literature. Part III
110. Composite tissue allotransplantation: A comprehensive review of the literature. Part II